Melanotan 1 vs Melanotan 2: Evidence, Safety, and FDA Status

Online discussions often use “Melanotan 1,” “Melanotan 2,” and “PT-141” as though they were interchangeable tanning peptides. They are not. Afamelanotide, Melanotan II, and bremelanotide are distinct molecules with different receptor activity, clinical evidence, approved uses, and safety concerns.

This distinction matters because approval of one precisely manufactured drug does not establish the identity, quality, safety, or effectiveness of an internet vial or nasal spray carrying a similar name. Neither afamelanotide nor Melanotan II is FDA-approved as a cosmetic tanning drug.

The short answer

• Melanotan I usually refers to afamelanotide, a linear 13-amino-acid melanocortin-1 receptor agonist. A specific 16 mg afamelanotide implant, Scenesse, is FDA-approved to increase pain-free light exposure in adults with erythropoietic protoporphyria (EPP). That approval is not for cosmetic tanning.
• Melanotan II is a distinct cyclic melanocortin agonist. Its human tanning evidence begins with a three-person pilot study, and it has no FDA-approved indication.
• Melanotan II is not bremelanotide. Bremelanotide is a related but separate drug marketed as Vyleesi for one narrowly defined sexual-health indication in premenopausal women. Its approval does not validate Melanotan II or tanning use.
• There is no evidence-based “safer tanning peptide” winner. Product uncertainty, incomplete safety data, and ultraviolet exposure remain central concerns. A tan does not replace sunscreen or other UV protection.

Comparison at a glance

Identity comes before comparison

“Melanotan I” is a research-era name commonly associated with afamelanotide. The FDA-approved product is not a generic endorsement of everything sold under that nickname: Scenesse is a characterized, controlled-release implant manufactured to a reviewed specification and administered by a trained healthcare professional.

Afamelanotide is not interchangeable with an internet product labeled Melanotan I. A matching name does not prove the sequence, dose, purity, sterility, release profile, or clinical performance of the approved implant.

Melanotan II has the sequence Ac-Nle-c[Asp-His-D-Phe-Arg-Trp-Lys]-NH2. Its cyclic structure and broader receptor activity distinguish it from afamelanotide. Bremelanotide was developed from the same research family, but it is a separate active ingredient with its own specification, evidence package, label, and risks.

What the afamelanotide evidence actually shows

An early randomized, placebo-controlled study enrolled 28 healthy white men and reported increased skin darkening after ten subcutaneous administrations over 12 days. All participants also used high-potency sunscreen. This study demonstrated a biological pigmentation effect under a small, controlled protocol; it did not establish long-term safety or approve cosmetic tanning products.

The strongest afamelanotide evidence addresses EPP, a rare disorder that causes painful phototoxic reactions. Two randomized, multicenter trials studied a 16 mg implant in 74 European and 94 US participants. Afamelanotide increased time in sunlight without pain, improved quality-of-life measures, and reduced phototoxic reactions in the European trial. Those outcomes supported disease-specific use, not a general tanning claim.

The current US Scenesse label is equally specific: the implant is indicated to increase pain-free light exposure in adults with a history of phototoxic reactions from EPP. It is administered every two months by a trained professional. Transferring that benefit-risk conclusion to a differently formulated research vial, spray, or cosmetic use would be scientifically invalid.

How limited is the Melanotan II evidence?

The first human pigmentation report was a phase I pilot involving only three healthy men. Two showed increased pigmentation. Mild nausea occurred at most dose levels, and investigators also observed stretching, yawning, spontaneous erections lasting one to five hours, fatigue, and somnolence at higher exposure.

That sample is far too small to estimate common risks reliably, detect uncommon harms, establish long-term safety, or compare Melanotan II with afamelanotide. Later crossover studies in ten men explored erectile response, not cosmetic tanning efficacy. Nausea and other systemic effects remained prominent; in one organic erectile-dysfunction study, severe nausea occurred after 4 of 19 Melanotan II administrations.

The evidence therefore supports a narrow conclusion: Melanotan II can affect pigmentation and other melanocortin-regulated systems. It does not support claims of predictable cosmetic results, an established long-term safety profile, or superiority over afamelanotide.

Why the receptor difference matters

Pigmentation is driven mainly through melanocortin-1 receptor signaling in melanocytes. Afamelanotide was developed around that target. Melanotan II has broader melanocortin activity, which helps explain why early studies recorded sexual responses, appetite changes, nausea, yawning, and stretching alongside pigmentation.

Mechanism alone cannot quantify clinical benefit or risk. Receptor selectivity measured in laboratory systems does not substitute for adequately powered human trials, validated manufacturing, or post-market surveillance.

Melanotan II and bremelanotide are not synonyms

Some product pages use “Melanotan II,” “PT-141,” and “bremelanotide” as interchangeable search terms. That collapses separate active ingredients and creates a serious sourcing problem.

The FDA-approved bremelanotide product, Vyleesi, is indicated for acquired, generalized HSDD in premenopausal women when the low desire causes marked distress and is not due to a medical or psychiatric condition, relationship problem, or drug effect. It is not approved to improve sexual performance, for use in men, or for tanning.

The Vyleesi label also describes clinically relevant risks, including transient blood-pressure increases, reduced heart rate, nausea, and focal hyperpigmentation. None of that approval evidence can be used as a proxy for the safety, identity, or effectiveness of Melanotan II.

Safety and uncertainty

Afamelanotide implant

The approved Scenesse label warns about hypersensitivity and notes that the drug may darken pre-existing nevi and ephelides. It recommends a full-body skin examination twice each year to monitor pigmentary lesions. Common adverse reactions in trials included implant-site reactions, nausea, skin hyperpigmentation, somnolence, melanocytic nevus, dizziness, and respiratory-tract infection.

These controls illustrate the difference between monitored medical use and unsupervised cosmetic use. Even for an approved formulation, skin surveillance and professional administration are part of the benefit-risk framework.

Melanotan II

Published case reports describe events including prolonged erections requiring urgent treatment and changes in melanocytic nevi. Case reports can identify safety signals but cannot, by themselves, prove that Melanotan II caused melanoma or another reported condition. Confounding factors such as ultraviolet exposure, tanning-bed use, underlying risk, and uncertain product contents must be considered.

The FDA currently lists Melanotan II among bulk substances whose use in compounded products may present significant safety risks. Its discussion cites concerns about immunogenicity from aggregation or peptide-related impurities and published reports involving melanoma, posterior reversible encephalopathy syndrome, sympathomimetic toxidrome, and priapism. This is a risk signal, not proof that every reported event was caused by the peptide.

The label may not match the contents

Unapproved online products add a separate layer of risk: uncertain identity and dose. In August 2026, Australia’s Therapeutic Goods Administration reported laboratory testing of five seized nasal sprays labeled as containing 30 mg of Melanotan II. Estimated contents ranged from 22 mg to 54 mg. That spread makes the printed dose an unreliable basis for exposure estimates.

Regulators also emphasize that peptide-induced pigmentation does not make deliberate UV exposure safe. Tanning beds and solar UV radiation still damage DNA and increase skin-cancer risk; darker skin does not replace broad-spectrum sunscreen, protective clothing, shade, or avoidance of tanning devices.

Current regulatory status

• Afamelanotide: the specific Scenesse 16 mg implant is FDA-approved for adults with EPP. Cosmetic tanning is not an approved use.
• Melanotan II: no FDA-approved product or indication.
• Bremelanotide: Vyleesi is FDA-approved for a narrowly defined HSDD indication in premenopausal women. It is not Melanotan II and is not a tanning drug.
• Internet tanning injections and nasal sprays: a product’s listing, label, or certificate does not confer regulatory approval. The FDA and TGA have both published safety concerns about unapproved melanotan products.

Because approvals and enforcement actions can change, verify current status directly in the relevant regulator’s database rather than relying on a seller’s summary.

Research-sourcing checks

For legitimate analytical or laboratory research, the first question is not “MT-1 or MT-2?” It is whether the material can be identified and characterized well enough for the intended experiment.

1. Exact identity: require the full peptide sequence, cyclization or bridge definition, N- and C-terminal modifications, and unambiguous compound name.
2. Salt and counterion: record whether the material is an acetate or another form because counterions affect reported mass and assay calculations.
3. Identity versus purity: mass spectrometry can support molecular identity; chromatographic purity describes the distribution of detected components. Neither alone establishes quantity, sterility, or biological activity.
4. Lot-specific assay: request a per-lot result that distinguishes net peptide content from total vial mass, water, counterions, and excipients.
5. Impurities and aggregation: review related substances, truncations, oxidation products, residual solvents, and aggregation controls appropriate to the experiment.
6. Route-specific controls: a nonsterile research material is not suitable for injection. A purity percentage does not establish sterility, endotoxin control, particulate control, or intranasal safety.
7. Packaging and label reconciliation: match the vial, lot number, report, and stated quantity. Large discrepancies between nominal and measured content can invalidate both safety assumptions and experimental results.

Our peptide source directory is an informational starting point for comparing disclosed research documentation. Inclusion is not an endorsement for human use. For the underlying evaluation standard, see the research methodology, sourcing policy, peptide purity testing guide, and peptide manufacturing guide.

Related reading

• Cosmetic Peptides Guide
• Peptide Purity Testing
• How Peptides Are Made
• Research Methodology
• Sourcing Policy
• Peptide Source Directory

References

1. US Food and Drug Administration. Scenesse (afamelanotide) prescribing information, revised 2024.
2. US Food and Drug Administration. Orphan Drug Designations and Approvals: afamelanotide.
3. Langendonk JG, et al. Afamelanotide for erythropoietic protoporphyria. New England Journal of Medicine. 2015.
4. Levine N, et al. Induction of skin tanning by subcutaneous administration of a potent synthetic melanotropin. JAMA. 1991.
5. Dorr RT, et al. Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study. Life Sciences. 1996.
6. Wessells H, et al. Effect of an alpha-melanocyte stimulating hormone analog on penile erection and sexual desire in men with organic erectile dysfunction. Urology. 2000.
7. US Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding May Present Significant Safety Risks.
8. US Food and Drug Administration. Vyleesi (bremelanotide) prescribing information.
9. Therapeutic Goods Administration. Melanotan II tanning peptide products found to be inconsistently dosed. 2026.
10. Therapeutic Goods Administration. Don’t risk using tanning products containing Melanotan. 2025.
11. Nelson ME, et al. Melanotan II injection resulting in systemic toxicity and rhabdomyolysis. Clinical Toxicology. 2012.
12. Cardones AR, et al. Melanotan II use and melanocytic nevi. Pediatrics. 2013.

Bottom line

Afamelanotide and Melanotan II should not be compared as two retail versions of the same tanning product. Afamelanotide has meaningful disease-specific evidence and one tightly controlled FDA-approved implant for EPP. Melanotan II has sparse human evidence, broader systemic effects, no approved indication, and substantial uncertainty around online products. Bremelanotide is a third, distinct drug whose approval cannot be borrowed to market Melanotan II.

For research, insist on exact molecular identity and lot-specific analytical evidence. For cosmetic tanning, neither peptide offers an FDA-approved route, and pigmentation does not remove the harms of ultraviolet exposure.